• Richard Lee, CEO of LOTTE BIOLOGICS, delivers a keynote speech at the JPM Healthcare Conference for the second consecutive year
• Unveils company's bio plant development plan in Songdo to meet clients' needs

The 42nd annual JPMHC is the largest event in the pharmaceutical and biotech industry, where global pharmaceutical giants, bio ventures, and healthcare investment experts converge to discuss research and development (R&D), fundraising, and partnerships.

For the second consecutive year, LOTTE BIOLOGICS attended the JPMHC, with CEO Richard Lee presenting in person. This year, he introduced LOTTE BIOLOGICS' plan to develop a bio plant in Incheon Songdo, emphasizing 'Design' as a key concept in bridging the gap between market demand and supply capabilities in the CDMO sector. Based on the experience of it's employees, CEO Lee presented the configuration plans for the Songdo bio plant, designed to fulfil it's clients' needs.

Mr. Lee remarked, "LOTTE BIOLOGICS' bio plant in Songdo will not just be a production facility, but embody innovative solutions for a better human life. We are committed to evolving as a global CDMO, ensuring on-time-in-full delivery of necessary pharmaceuticals to patients."

Last October, LOTTE BIOLOGICS signed a land purchase agreement with the Incheon Free Economic Zone Authority (IFEZ) to build a bio plant in Songdo International City, Incheon. By 2030, LOTTE BIOLOGICS plans to construct three bio plants at the KI20 Block of Songdo's 11th District, (418, 418-9 Songdo-dong, Yeonsu-gu, Incheon), achieving a total antibody medicine production capacity of 360,000 liters.